{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T11:22:01Z","timestamp":1788434521785,"version":"build-2803163510"},"reference-count":80,"publisher":"IMR Press","issue":"8","license":[{"start":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T00:00:00Z","timestamp":1787184000000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Rev. Neurol."],"abstract":"<jats:p>The 18th edition of the post-European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) meeting was held on 17\u201318 October 2025 in Madrid, bringing together Spanish neurologists specialising in multiple sclerosis (MS), who presented the most relevant advances discussed at the ECTRIMS congress held a few days earlier in Barcelona. The aim of this edition was to present the latest developments in MS regarding the update of diagnostic criteria, advanced neuroimaging techniques, the role of Epstein-Barr virus, remyelination mechanisms and biomarkers. In the therapeutic field, emerging treatments were addressed, such as new monoclonal antibodies and chimeric antigen receptor T cells (CAR-T), the management of elderly patients and the risks associated with high-efficacy therapies. This article is the second of a two-part series (I and II). The article reviews recent data on disease progression and on the concept of progression independent of relapse activity (PIRA), including the definition, among those published, that leads to balanced incidence and persistence in PIRA rates. Certain neuropathological and imaging aspects are reviewed, and, with regard to serum biomarkers, it is emphasised that neurofilament light chain (NfL) is a marker of acute damage that is not specific to MS, and that the challenge lies in establishing a value that differentiates it from other diseases. It is also discussed whether the low sensitivity of NfL for predicting progression lies in the z-score used in clinical practice, and the usefulness of glial fibrillary acidic protein (GFAP) in combination with NfL to refine the assessment of chronic progressive damage. The importance of age in MS is indisputable. The elderly patient with MS has a greater number of comorbidities and is more vulnerable to certain treatments. Menopause is a normal but expected physiological transition of female ageing that may trigger or aggravate certain health problems, and whose symptoms should not be confused with worsening of the disease. As for cognitive impairment in MS, the latest developments and expert opinions that could help improve its identification and monitoring are summarised. Much of this part II article focuses on summarising the key advances in emerging therapies and treatment prospects in related diseases, without overlooking the risks associated with very high-efficacy therapies and the possible risk-prevention strategies. Finally, as important findings that translate into clinical practice, the notable improvement in diagnosis with the new 2024 McDonald criteria stands out, despite the barriers to accessing paraclinical tests in certain populations. Overall, the data reviewed, together with those gathered in part I, reflect the research effort to advance the understanding of the disease from multiple complementary perspectives, which is transforming the care of patients with MS.<\/jats:p>","DOI":"10.31083\/rn55658","type":"journal-article","created":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T11:04:40Z","timestamp":1788433480000},"source":"Crossref","is-referenced-by-count":0,"title":["XVIII Post-ECTRIMS Meeting: Review of the New Developments Presented at the 2025 ECTRIMS Congress (Part II)"],"prefix":"10.31083","volume":"81","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3696-789X","authenticated-orcid":true,"given":"\u00d3scar","family":"Fern\u00e1ndez","sequence":"first","affiliation":[{"name":"Departamento de Farmacolog\u00eda, Facultad de Medicina, Universidad de M\u00e1laga, 29016 M\u00e1laga, Espa\u00f1a"},{"name":"Instituto de Investigaci\u00f3n Biom\u00e9dica de M\u00e1laga (IBIMA), Hospital Universitario Regional de M\u00e1laga, Universidad de M\u00e1laga, 29016 M\u00e1laga, Espa\u00f1a"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0098-9918","authenticated-orcid":true,"given":"Xavier","family":"Montalban","sequence":"additional","affiliation":[{"name":"Centro de Esclerosis M\u00faltiple de Catalu\u00f1a y Departamento de Neurolog\u00eda, Hospital Universitario Vall d\u2019Hebron, 08035 Barcelona, Espa\u00f1a"},{"name":"Universitat Aut\u00f2noma de Barcelona, 08193 Bellaterra, Espa\u00f1a"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5193-3001","authenticated-orcid":true,"given":"Adri\u00e1n","family":"Ar\u00e9s","sequence":"additional","affiliation":[{"name":"Servicio de Neurolog\u00eda, Complejo Asistencial Universitario de Le\u00f3n, 24008 Le\u00f3n, Espa\u00f1a"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8604-2054","authenticated-orcid":true,"given":"Eduardo","family":"Ag\u00fcera","sequence":"additional","affiliation":[{"name":"Servicio de Neurolog\u00eda, Hospital Reina Sof\u00eda, 14004 C\u00f3rdoba, Espa\u00f1a"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9459-5452","authenticated-orcid":true,"given":"Yolanda","family":"Aladro","sequence":"additional","affiliation":[{"name":"Servicio de Neurolog\u00eda, Hospital Universitario de Getafe, 28905 Getafe, Espa\u00f1a"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7337-8384","authenticated-orcid":true,"given":"Ana","family":"Alonso","sequence":"additional","affiliation":[{"name":"Unidad de Esclerosis M\u00faltiple, Servicio de Neurolog\u00eda, Hospital Regional Universitario de M\u00e1laga, 29010 M\u00e1laga, Espa\u00f1a"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3137-6954","authenticated-orcid":true,"given":"Rafael","family":"Arroyo","sequence":"additional","affiliation":[{"name":"Servicio de Neurolog\u00eda, Hospital Universitario Quir\u00f3nsalud, 28223 Pozuelo de Alarc\u00f3n, Espa\u00f1a"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5871-6189","authenticated-orcid":true,"given":"Luis","family":"Brieva","sequence":"additional","affiliation":[{"name":"Universitat de Lleida, 25198 Lleida, Espa\u00f1a"},{"name":"Hospital Universitari Arnau de Vilanova, Institut de Recerca Biom\u00e8dica de Lleida (IRBLleida), 25198 Lleida, Espa\u00f1a"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2275-8416","authenticated-orcid":true,"given":"Carmen","family":"Calles","sequence":"additional","affiliation":[{"name":"Servicio de Neurolog\u00eda, Hospital Universitario Son Espases, 07120 Palma de Mallorca, Espa\u00f1a"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-7121-4112","authenticated-orcid":true,"given":"Ana Bel\u00e9n","family":"Caminero","sequence":"additional","affiliation":[{"name":"Servicio de Neurolog\u00eda, Complejo Asistencial de \u00c1vila, 05071 \u00c1vila, Espa\u00f1a"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9249-3185","authenticated-orcid":true,"given":"Tamara","family":"Castillo-Trivi\u00f1o","sequence":"additional","affiliation":[{"name":"Servicio de Neurolog\u00eda, Hospital Universitario Donostia, Grupo de Neuroinmunolog\u00eda, IIS Biogipuzkoa, 20014 Donostia, Espa\u00f1a"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6512-4413","authenticated-orcid":true,"given":"Lucienne","family":"Costa-Frossard","sequence":"additional","affiliation":[{"name":"CSUR de Esclerosis M\u00faltiple, Hospital Ram\u00f3n y Cajal, 28034 Madrid, Espa\u00f1a"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"Eichau","sequence":"additional","affiliation":[{"name":"Servicio de Neurolog\u00eda, Hospital Universitario Virgen Macarena, 41009 Sevilla, Espa\u00f1a"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2836-129X","authenticated-orcid":true,"given":"Lamberto","family":"Landete","sequence":"additional","affiliation":[{"name":"Servicio de Neurolog\u00eda, Hospital Universitario Doctor Peset, 46017 Valencia, Espa\u00f1a"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9817-3230","authenticated-orcid":true,"given":"Miguel","family":"Llaneza","sequence":"additional","affiliation":[{"name":"Servicio de Neurolog\u00eda, Hospital Universitario Central de Asturias, 33011 Oviedo, Espa\u00f1a"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4273-9121","authenticated-orcid":true,"given":"Sara","family":"Llufriu","sequence":"additional","affiliation":[{"name":"Unidad de Neuroinmunolog\u00eda y Esclerosis M\u00faltiple, Hospital Cl\u00ednic de Barcelona e IDIBAPS, 08036 Barcelona, Espa\u00f1a"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5050-9890","authenticated-orcid":true,"given":"Jos\u00e9 E.","family":"Meca-Lallana","sequence":"additional","affiliation":[{"name":"CSUR Esclerosis M\u00faltiple, Unidad de Neuroinmunolog\u00eda Cl\u00ednica, Servicio de Neurolog\u00eda, Hospital Cl\u00ednico Universitario Virgen de la Arrixaca (IMIB-Arrixaca), 30120 El Palmar, Espa\u00f1a"},{"name":"C\u00e1tedra de Neuroinmunolog\u00eda Cl\u00ednica y Esclerosis M\u00faltiple, Universidad Cat\u00f3lica San Antonio (UCAM), 30107 Guadalupe, Espa\u00f1a"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9418-4127","authenticated-orcid":true,"given":"Virginia","family":"Meca-Lallana","sequence":"additional","affiliation":[{"name":"Servicio de Neurolog\u00eda, Hospital Universitario de la Princesa, 28006 Madrid, Espa\u00f1a"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3293-0125","authenticated-orcid":true,"given":"Enric","family":"Monreal","sequence":"additional","affiliation":[{"name":"CSUR de Esclerosis M\u00faltiple, Hospital Ram\u00f3n y Cajal, 28034 Madrid, Espa\u00f1a"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6243-9092","authenticated-orcid":true,"given":"Ester","family":"Moral","sequence":"additional","affiliation":[{"name":"Servicio de Neurolog\u00eda, Complejo Hospitalario Universitario Mois\u00e8s Broggi, 08970 Barcelona, Espa\u00f1a"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9221-5716","authenticated-orcid":true,"given":"Celia","family":"Oreja-Guevara","sequence":"additional","affiliation":[{"name":"Servicio de Neurolog\u00eda, Hospital Cl\u00ednico San Carlos, Instituto de Investigaci\u00f3n Sanitaria San Carlos (IdISSC), 28040 Madrid, Espa\u00f1a"},{"name":"Departamento de Medicina, Facultad de Medicina, Universidad Complutense de Madrid (UCM), 28040 Madrid, Espa\u00f1a"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8170-0724","authenticated-orcid":true,"given":"Jos\u00e9 Mar\u00eda","family":"Prieto","sequence":"additional","affiliation":[{"name":"Servicio de Neurolog\u00eda, Instituto de Investigaci\u00f3n Sanitaria de Santiago de Compostela (IDIS), 15706 Santiago de Compostela, Espa\u00f1a"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8054-0565","authenticated-orcid":true,"given":"Luc\u00eda","family":"Romero-Pinel","sequence":"additional","affiliation":[{"name":"Hospital Universitari de Bellvitge-Institut d'Investigaci\u00f3 Biom\u00e8dica de Bellvitge (IDIBELL), 08908 L\u2019Hospitalet de Llobregat, Espa\u00f1a"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2132-6750","authenticated-orcid":true,"given":"\u00c0lex","family":"Rovira","sequence":"additional","affiliation":[{"name":"Secci\u00f3n de Neuroradiolog\u00eda, Departamento de Radiolog\u00eda, Hospital Universitari Vall d'Hebron, 08035 Barcelona, Espa\u00f1a"},{"name":"Universitat Aut\u00f2noma de Barcelona, 08193 Barcelona, Espa\u00f1a"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4566-2329","authenticated-orcid":true,"given":"Alfredo","family":"Rodr\u00edguez-Antig\u00fcedad","sequence":"additional","affiliation":[{"name":"Servicio de Neurolog\u00eda, Hospital Universitario Cruces, 48903 Barakaldo, Espa\u00f1a"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"16242","published-online":{"date-parts":[[2026,8,20]]},"reference":[{"key":"ref1","unstructured":"Stadelmann C. Neuropathologic and molecular processes underlying neurodegeneration and progression. In 41st Congress of the European Committee for Treatment and Research in Multiple Sclerosis and the 30th Conference of Rehabilitation in Multiple Sclerosis. Barcelona, Spain. 2025."},{"key":"ref2","doi-asserted-by":"publisher","unstructured":"Klotz L, Smolders J, Lehto J, Matilainen M, L\u00fctje L, Buchholz L, et al. Broad rim lesions are a new pathological and imaging biomarker for rapid disease progression in multiple sclerosis. Nature Medicine. 2025; 31: 2016\u20132026.","DOI":"10.1038\/s41591-025-03625-7"},{"key":"ref3","doi-asserted-by":"publisher","unstructured":"Herranz E, Treaba CA, Barletta VT, Mehndiratta A, Ouellette R, Sloane JA, et al. Characterization of cortico-meningeal translocator protein expression in multiple sclerosis. Brain: a Journal of Neurology. 2024; 147: 2566\u20132578.","DOI":"10.1093\/brain\/awae030"},{"key":"ref4","unstructured":"Bittner S. Clinical implementation of fluid biomarker detecting and monitoring neurodegeneration and progression. In 41st Congress of the European Committee for Treatment and Research in Multiple Sclerosis and the 30th Conference of Rehabilitation in Multiple Sclerosis. Barcelona, Spain. 2025."},{"key":"ref5","doi-asserted-by":"publisher","unstructured":"Ciccarelli O, Barkhof F, Calabrese M, De Stefano N, Eshaghi A, Filippi M, et al. Using the Progression Independent of Relapse Activity Framework to Unveil the Pathobiological Foundations of Multiple Sclerosis. Neurology. 2024; 103: e209444.","DOI":"10.1212\/WNL.0000000000209444"},{"key":"ref6","doi-asserted-by":"publisher","unstructured":"Montobbio N, Carmisciano L, Signori A, Ponzano M, Schiavetti I, Bovis F, et al. Creating an automated tool for a consistent and repeatable evaluation of disability progression in clinical studies for multiple sclerosis. Multiple Sclerosis (Houndmills, Basingstoke, England). 2024; 30: 1185\u20131192.","DOI":"10.1177\/13524585241243157"},{"key":"ref7","doi-asserted-by":"publisher","unstructured":"M\u00fcller J, Sharmin S, Lorscheider J, Ozakbas S, Karabudak R, Horakova D, et al. Standardized Definition of Progression Independent of Relapse Activity (PIRA) in Relapsing-Remitting Multiple Sclerosis. JAMA Neurology. 2025; 82: 614\u2013625.","DOI":"10.1001\/jamaneurol.2025.0495"},{"key":"ref8","doi-asserted-by":"publisher","unstructured":"Montobbio N, Bovis F, Signori A, Carmisciano L, Schiavetti I, Ponzano M, et al. Uncovering a bias in estimated treatment effects on PIRA in multiple sclerosis clinical trials. EBioMedicine. 2025; 117: 105802.","DOI":"10.1016\/j.ebiom.2025.105802"},{"key":"ref9","doi-asserted-by":"publisher","unstructured":"Kappos L, Wolinsky JS, Giovannoni G, Arnold DL, Wang Q, Bernasconi C, et al. Contribution of Relapse-Independent Progression vs Relapse-Associated Worsening to Overall Confirmed Disability Accumulation in Typical Relapsing Multiple Sclerosis in a Pooled Analysis of 2 Randomized Clinical Trials. JAMA Neurology. 2020; 77: 1132\u20131140.","DOI":"10.1001\/jamaneurol.2020.1568"},{"key":"ref10","unstructured":"Fuchs TA. Cognitive progression independent of relapse in multiple sclerosis: multi-center characterization. In 41st Congress of the European Committee for Treatment and Research in Multiple Sclerosis and the 30th Conference of Rehabilitation in Multiple Sclerosis. Barcelona, Spain. 2025."},{"key":"ref11","doi-asserted-by":"publisher","unstructured":"Cagol A, Schaedelin S, Barakovic M, Benkert P, Todea RA, Rahmanzadeh R, et al. Association of Brain Atrophy With Disease Progression Independent of Relapse Activity in Patients With Relapsing Multiple Sclerosis. JAMA Neurology. 2022; 79: 682\u2013692.","DOI":"10.1001\/jamaneurol.2022.1025"},{"key":"ref12","doi-asserted-by":"publisher","unstructured":"Fissolo N, Benkert P, Sastre-Garriga J, Mongay-Ochoa N, Vilaseca-Jolonch A, Llufriu S, et al. Serum biomarker levels predict disability progression in patients with primary progressive multiple sclerosis. Journal of Neurology, Neurosurgery, and Psychiatry. 2024; 95: 410\u2013418.","DOI":"10.1136\/jnnp-2023-332251"},{"key":"ref13","unstructured":"Mycko M. MS in the aging brain: the immunopathological perspective. In 41st Congress of the European Committee for Treatment and Research in Multiple Sclerosis and the 30th Conference of Rehabilitation in Multiple Sclerosis. Barcelona, Spain. 2025."},{"key":"ref14","doi-asserted-by":"publisher","unstructured":"Montalban X, Lebrun-Fr\u00e9nay C, Oh J, Arrambide G, Moccia M, Pia Amato M, et al. Diagnosis of multiple sclerosis: 2024 revisions of the McDonald criteria. The Lancet. Neurology. 2025; 24: 850\u2013865.","DOI":"10.1016\/S1474-4422(25)00270-4"},{"key":"ref15","unstructured":"Magyari M. Late-onset multiple sclerosis. In 41st Congress of the European Committee for Treatment and Research in Multiple Sclerosis and the 30th Conference of Rehabilitation in Multiple Sclerosis. Barcelona, Spain. 2025."},{"key":"ref16","doi-asserted-by":"publisher","unstructured":"Gelibter S, Saraceno L, Pirro F, Susani EL, Protti A. As time goes by: Treatment challenges in elderly people with multiple sclerosis. Journal of Neuroimmunology. 2024; 391: 578368.","DOI":"10.1016\/j.jneuroim.2024.578368"},{"key":"ref17","doi-asserted-by":"publisher","unstructured":"Weideman AM, Tapia-Maltos MA, Johnson K, Greenwood M, Bielekova B. Meta-analysis of the Age-Dependent Efficacy of Multiple Sclerosis Treatments. Frontiers in Neurology. 2017; 8: 577.","DOI":"10.3389\/fneur.2017.00577"},{"key":"ref18","doi-asserted-by":"publisher","unstructured":"Zhang Y, Gonzalez Caldito N, Shirani A, Salter A, Cutter G, Culpepper W, 2nd, et al. Aging and efficacy of disease-modifying therapies in multiple sclerosis: a meta-analysis of clinical trials. Therapeutic Advances in Neurological Disorders. 2020; 13: 1756286420969016.","DOI":"10.1177\/1756286420969016"},{"key":"ref19","doi-asserted-by":"publisher","unstructured":"Luna G, Alping P, Burman J, Fink K, Fogdell-Hahn A, Gunnarsson M, et al. Infection Risks Among Patients With Multiple Sclerosis Treated With Fingolimod, Natalizumab, Rituximab, and Injectable Therapies. JAMA Neurology. 2020; 77: 184\u2013191.","DOI":"10.1001\/jamaneurol.2019.3365"},{"key":"ref20","doi-asserted-by":"publisher","unstructured":"Prosperini L, Haggiag S, Tortorella C, Galgani S, Gasperini C. Age-related adverse events of disease-modifying treatments for multiple sclerosis: A meta-regression. Multiple Sclerosis (Houndmills, Basingstoke, England). 2021; 27: 1391\u20131402.","DOI":"10.1177\/1352458520964778"},{"key":"ref21","doi-asserted-by":"publisher","unstructured":"Mouresan EF, Mentesidou E, Berglund A, McKay KA, Hillert J, Iacobaeus E. Clinical Characteristics and Long-Term Outcomes of Late-Onset Multiple Sclerosis: A Swedish Nationwide Study. Neurology. 2024; 102: e208051.","DOI":"10.1212\/WNL.0000000000208051"},{"key":"ref22","unstructured":"Van der Walt A. Strategies for treating older people with MS. In 41st Congress of the European Committee for Treatment and Research in Multiple Sclerosis and the 30th Conference of Rehabilitation in Multiple Sclerosis. Barcelona, Spain. 2025."},{"key":"ref23","doi-asserted-by":"publisher","unstructured":"Giovannoni G, Ford HL, Schmierer K, Middleton R, Stennett AM, Pomeroy I, et al. MS care: integrating advanced therapies and holistic management. Frontiers in Neurology. 2024; 14: 1286122.","DOI":"10.3389\/fneur.2023.1286122"},{"key":"ref24","unstructured":"Graves J. MS treatment management in older patients: choices and challenges. In 41st Congress of the European Committee for Treatment and Research in Multiple Sclerosis and the 30th Conference of Rehabilitation in Multiple Sclerosis. Barcelona, Spain. 2025."},{"key":"ref25","doi-asserted-by":"publisher","unstructured":"Goyne C, Fair AE, Yilmaz D, Race J, Schuette A, Caillier SJ, et al. Epigenetic Aging in Pediatric-Onset Multiple Sclerosis. Neurology. 2025; 104: e213673.","DOI":"10.1212\/WNL.0000000000213673"},{"key":"ref26","doi-asserted-by":"publisher","unstructured":"Arsenis NC, You T, Ogawa EF, Tinsley GM, Zuo L. Physical activity and telomere length: Impact of aging and potential mechanisms of action. Oncotarget. 2017; 8: 45008\u201345019.","DOI":"10.18632\/oncotarget.16726"},{"key":"ref27","doi-asserted-by":"publisher","unstructured":"Canudas S, Becerra-Tom\u00e1s N, Hern\u00e1ndez-Alonso P, Gali\u00e9 S, Leung C, Crous-Bou M, et al. Mediterranean Diet and Telomere Length: A Systematic Review and Meta-Analysis. Advances in Nutrition (Bethesda, Md.). 2020; 11: 1544\u20131554.","DOI":"10.1093\/advances\/nmaa079"},{"key":"ref28","doi-asserted-by":"publisher","unstructured":"Marrie RA, Fisk JD, Fitzgerald K, Kowalec K, Maxwell C, Rotstein D, et al. Etiology, effects and management of comorbidities in multiple sclerosis: recent advances. Frontiers in Immunology. 2023; 14: 1197195.","DOI":"10.3389\/fimmu.2023.1197195"},{"key":"ref29","unstructured":"Oreja-Guevara C. Menopause and MS: hormonal factors and disease evolution. In 41st Congress of the European Committee for Treatment and Research in Multiple Sclerosis and the 30th Conference of Rehabilitation in Multiple Sclerosis. Barcelona, Spain. 2025."},{"key":"ref30","doi-asserted-by":"publisher","unstructured":"Koch MW, Mostert JP, Uitdehaag B, Cutter G. A comparison of clinical outcomes in PPMS in the INFORMS original trial data set. Multiple Sclerosis (Houndmills, Basingstoke, England). 2021; 27: 1864\u20131874.","DOI":"10.1177\/1352458520987539"},{"key":"ref31","doi-asserted-by":"publisher","unstructured":"Koch MW, Mostert J, Repovic P, Bowen JD, Uitdehaag B, Cutter G. Is the Symbol Digit Modalities Test a useful outcome in secondary progressive multiple sclerosis? European Journal of Neurology. 2021; 28: 2115\u20132120.","DOI":"10.1111\/ene.14732"},{"key":"ref32","doi-asserted-by":"publisher","unstructured":"Castrogiovanni N, Mostert J, Repovic P, Bowen JD, Uitdehaag BMJ, Strijbis EMM, et al. Longitudinal Changes in Cognitive Test Scores in Patients With Relapsing-Remitting Multiple Sclerosis: An Analysis of the DECIDE Dataset. Neurology. 2023; 101: e1\u2013e11.","DOI":"10.1212\/WNL.0000000000207301"},{"key":"ref33","doi-asserted-by":"publisher","unstructured":"Leavitt V, Mostert J, Comtois J, Moral E, Brieva L, Repovic P, et al. Measuring cognitive change in secondary progressive MS: an analysis of the ASCEND cognition substudy. Journal of Neurology. 2025; 272: 338.","DOI":"10.1007\/s00415-025-13066-4"},{"key":"ref34","doi-asserted-by":"publisher","unstructured":"El-Wahsh S, Ballard K, Kumfor F, Bogaardt H. Prevalence of self-reported language impairment in multiple sclerosis and the association with health-related quality of life: An international survey study. Multiple Sclerosis and Related Disorders. 2020; 39: 101896.","DOI":"10.1016\/j.msard.2019.101896"},{"key":"ref35","doi-asserted-by":"publisher","unstructured":"Sandry J, Simonet DV, Brandstadter R, Krieger S, Katz Sand I, Graney RA, et al. The Symbol Digit Modalities Test (SDMT) is sensitive but non-specific in MS: Lexical access speed, memory, and information processing speed independently contribute to SDMT performance. Multiple Sclerosis and Related Disorders. 2021; 51: 102950.","DOI":"10.1016\/j.msard.2021.102950"},{"key":"ref36","doi-asserted-by":"publisher","unstructured":"Tomasi D, Volkow ND. Resting functional connectivity of language networks: characterization and reproducibility. Molecular Psychiatry. 2012; 17: 841\u2013854.","DOI":"10.1038\/mp.2011.177"},{"key":"ref37","unstructured":"Wiendl H. BTK inhibitors: Evidence and expectations. In 41st Congress of the European Committee for Treatment and Research in Multiple Sclerosis and the 30th Conference of Rehabilitation in Multiple Sclerosis. Barcelona, Spain. 2025."},{"key":"ref38","unstructured":"Oh J. Fenebrutinib maintains early and sustained low disease activity in patients with relapsing multiple sclerosis: 2-year results from the FENopta open-label extension. In 41st Congress of the European Committee for Treatment and Research in Multiple Sclerosis and the 30th Conference of Rehabilitation in Multiple Sclerosis. Barcelona, Spain. 2025."},{"key":"ref39","unstructured":"Cross A. Could targeting anti-CD19 work better than targeting anti-CD20 in MS? In 41st Congress of the European Committee for Treatment and Research in Multiple Sclerosis and the 30th Conference of Rehabilitation in Multiple Sclerosis. Barcelona, Spain. 2025."},{"key":"ref40","doi-asserted-by":"publisher","unstructured":"Frischer JM, Bramow S, Dal-Bianco A, Lucchinetti CF, Rauschka H, Schmidbauer M, et al. The relation between inflammation and neurodegeneration in multiple sclerosis brains. Brain: a Journal of Neurology. 2009; 132: 1175\u20131189.","DOI":"10.1093\/brain\/awp070"},{"key":"ref41","doi-asserted-by":"publisher","unstructured":"Herbst R, Wang Y, Gallagher S, Mittereder N, Kuta E, Damschroder M, et al. B-cell depletion in vitro and in vivo with an afucosylated anti-CD19 antibody. The Journal of Pharmacology and Experimental Therapeutics. 2010; 335: 213\u2013222.","DOI":"10.1124\/jpet.110.168062"},{"key":"ref42","doi-asserted-by":"publisher","unstructured":"Agius MA, Klodowska-Duda G, Maciejowski M, Potemkowski A, Li J, Patra K, et al. Safety and tolerability of inebilizumab (MEDI-551), an anti-CD19 monoclonal antibody, in patients with relapsing forms of multiple sclerosis: Results from a phase 1 randomised, placebo-controlled, escalating intravenous and subcutaneous dose study. Multiple Sclerosis (Houndmills, Basingstoke, England). 2019; 25: 235\u2013245.","DOI":"10.1177\/1352458517740641"},{"key":"ref43","doi-asserted-by":"crossref","unstructured":"Chitnis T, Singhal T, Zurawski J, Saraceno TJ, Gopalakrishnan N, Cain L, et al. Nasal foralumab treatment of PIRA induces regulatory immunity, dampens microglial activation and stabilizes clinical progression in non-active secondary progressive MS. medRxiv. 2025. (preprint)","DOI":"10.1101\/2025.04.30.25326602"},{"key":"ref44","unstructured":"Vermersch P. Safety and efficacy of frexalimab in participants with relapsing multiple sclerosis: 2.5-year results from the phase 2 open-label extension. In 41st Congress of the European Committee for Treatment and Research in Multiple Sclerosis and the 30th Conference of Rehabilitation in Multiple Sclerosis. Barcelona, Spain. 2025."},{"key":"ref45","unstructured":"Bar-Or A. Long-term treatment effect of frexalimab on NfL and plasma biomarkers of adaptive and innate immunity. In 41st Congress of the European Committee for Treatment and Research in Multiple Sclerosis and the 30th Conference of Rehabilitation in Multiple Sclerosis. Barcelona, Spain. 2025."},{"key":"ref46","doi-asserted-by":"publisher","unstructured":"Shah K, Leandro M, Cragg M, Kollert F, Schuler F, Klein C, et al. Disrupting B and T-cell collaboration in autoimmune disease: T-cell engagers versus CAR T-cell therapy? Clinical and Experimental Immunology. 2024; 217: 15\u201330.","DOI":"10.1093\/cei\/uxae031"},{"key":"ref47","unstructured":"Dunn J. Chimeric Antigen Receptor T Cell (CAR-T) Immunotherapy for Progressive Phenotypes of Multiple Sclerosis: early results from a Phase 1, Open-Label, Single Center Study of an Autologous Fully-Humanized Anti-CD19 CAR-T. In 41st Congress of the European Committee for Treatment and Research in Multiple Sclerosis and the 30th Conference of Rehabilitation in Multiple Sclerosis. Barcelona, Spain. 2025."},{"key":"ref48","unstructured":"Giovannoni G. Efficacy and safety of ocrelizumab vs placebo in primary progressive MS: Results of the Phase IIIb ORATORIO-HAND study. In 41st Congress of the European Committee for Treatment and Research in Multiple Sclerosis and the 30th Conference of Rehabilitation in Multiple Sclerosis. Barcelona, Spain. 2025."},{"key":"ref49","unstructured":"Hauser SL. Efficacy and safety of a body-weight\u2013adjusted high dose of ocrelizumab vs standard dose in PPMS: primary results of the Phase IIIb GAVOTTE study. In 41st Congress of the European Committee for Treatment and Research in Multiple Sclerosis and the 30th Conference of Rehabilitation in Multiple Sclerosis. Barcelona, Spain. 2025."},{"key":"ref50","unstructured":"Banwell B. Efficacy and safety of ocrelizumab compared with fingolimod in paediatric relapsing-remitting MS: results of the Phase III OPERETTA 2 study. In 41st Congress of the European Committee for Treatment and Research in Multiple Sclerosis and the 30th Conference of Rehabilitation in Multiple Sclerosis. Barcelona, Spain. 2025."},{"key":"ref51","unstructured":"Svenningsson A. RItuximab long-term DOSE trial in Multiple Sclerosis - RIDOSE-MS. A phase 3 trial investigating extended dosing regimen of rituximab in relapsing-remitting MS. In 41st Congress of the European Committee for Treatment and Research in Multiple Sclerosis and the 30th Conference of Rehabilitation in Multiple Sclerosis. Barcelona, Spain. 2025."},{"key":"ref52","unstructured":"Ramanathan S. Current and future treatments for NMOSD and MOGAD. In 41st Congress of the European Committee for Treatment and Research in Multiple Sclerosis and the 30th Conference of Rehabilitation in Multiple Sclerosis. Barcelona, Spain. 2025."},{"key":"ref53","doi-asserted-by":"publisher","unstructured":"Qin C, Tian DS, Zhou LQ, Shang K, Huang L, Dong MH, et al. Anti-BCMA CAR T-cell therapy CT103A in relapsed or refractory AQP4-IgG seropositive neuromyelitis optica spectrum disorders: phase 1 trial interim results. Signal Transduction and Targeted Therapy. 2023; 8: 5.","DOI":"10.1038\/s41392-022-01278-3"},{"key":"ref54","doi-asserted-by":"publisher","unstructured":"Trewin BP, Dale RC, Qiu J, Chu M, Jeyakumar N, Dela Cruz F, et al. Oral corticosteroid dosage and taper duration at onset in myelin oligodendrocyte glycoprotein antibody-associated disease influences time to first relapse. Journal of Neurology, Neurosurgery, and Psychiatry. 2024; 95: 1054\u20131063.","DOI":"10.1136\/jnnp-2024-333463"},{"key":"ref55","doi-asserted-by":"publisher","unstructured":"Lotan I, Chen JJ, Hacohen Y, Abdel-Mannan O, Mariotto S, Huda S, et al. Intravenous immunoglobulin treatment for acute attacks in myelin oligodendrocyte glycoprotein antibody disease. Multiple Sclerosis (Houndmills, Basingstoke, England). 2023; 29: 1080\u20131089.","DOI":"10.1177\/13524585231184738"},{"key":"ref56","doi-asserted-by":"publisher","unstructured":"Thakolwiboon S, Redenbaugh V, Chen B, Hewitt S, Shah S, Lotan I, et al. Outcomes After Acute Plasma Exchange for Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease. Neurology. 2025; 105: e213903.","DOI":"10.1212\/WNL.0000000000213903"},{"key":"ref57","doi-asserted-by":"publisher","unstructured":"Ringelstein M, Ayzenberg I, Lindenblatt G, Fischer K, Gahlen A, Novi G, et al. Interleukin-6 Receptor Blockade in Treatment-Refractory MOG-IgG-Associated Disease and Neuromyelitis Optica Spectrum Disorders. Neurology(R) Neuroimmunology & Neuroinflammation. 2021; 9: e1100.","DOI":"10.1212\/NXI.0000000000001100"},{"key":"ref58","doi-asserted-by":"publisher","unstructured":"Pittock SJ, Barnett M, Bennett JL, Berthele A, de S\u00e8ze J, Levy M, et al. Ravulizumab in Aquaporin-4-Positive Neuromyelitis Optica Spectrum Disorder. Annals of Neurology. 2023; 93: 1053\u20131068.","DOI":"10.1002\/ana.26626"},{"key":"ref59","unstructured":"Otero-Romero S. Vaccines and DMTs: an increasingly closer friendship. In 41st Congress of the European Committee for Treatment and Research in Multiple Sclerosis and the 30th Conference of Rehabilitation in Multiple Sclerosis. Barcelona, Spain. 2025."},{"key":"ref60","unstructured":"Carvajal R. Live attenuated vaccines and relapse risk in multiple sclerosis. In 41st Congress of the European Committee for Treatment and Research in Multiple Sclerosis and the 30th Conference of Rehabilitation in Multiple Sclerosis. Barcelona, Spain. 2025."},{"key":"ref61","doi-asserted-by":"publisher","unstructured":"Yeola A, Houston S, Aggarwal A, Gamage R, Maltby VE, Fabis-Pedrini MJ, et al. COVID-19 Vaccine Boosters in People With Multiple Sclerosis: Improved SARS-CoV-2 Cross-Variant Antibody Response and Prediction of Protection. Neurology(R) Neuroimmunology & Neuroinflammation. 2025; 12: e200443.","DOI":"10.1212\/NXI.0000000000200443"},{"key":"ref62","doi-asserted-by":"publisher","unstructured":"Carvajal R, Guananga-\u00c1lvarez D, Tur C, Esperalba J, Rodr\u00edguez-Barranco M, Rando-Segura A, et al. Effect of the Number of Vaccine Doses Before Starting Anti-CD20 Therapy on Seroprotection Rates Against Hepatitis B Virus in People With MS. Neurology. 2025; 104: e210281.","DOI":"10.1212\/WNL.0000000000210281"},{"key":"ref63","doi-asserted-by":"publisher","unstructured":"Carvajal R, Zabalza A, Carbonell-Mirabent P, Mart\u00ednez-G\u00f3mez X, Esperalba J, Pappolla A, et al. Vaccine Safety and Immunogenicity in Patients With Multiple Sclerosis Treated With Natalizumab. JAMA Network Open. 2024; 7: e246345.","DOI":"10.1001\/jamanetworkopen.2024.6345"},{"key":"ref64","unstructured":"van Kempen Z. Cumulative time on treatment vs cumulative treatments over time - impact on risk of adverse events. In 41st Congress of the European Committee for Treatment and Research in Multiple Sclerosis and the 30th Conference of Rehabilitation in Multiple Sclerosis. Barcelona, Spain. 2025."},{"key":"ref65","doi-asserted-by":"publisher","unstructured":"Androdias G, L\u00fcnemann JD, Maillart E, Amato MP, Audoin B, Bruijstens AL, et al. De-escalating and discontinuing disease-modifying therapies in multiple sclerosis. Brain: a Journal of Neurology. 2025; 148: 1459\u20131478.","DOI":"10.1093\/brain\/awae409"},{"key":"ref66","doi-asserted-by":"publisher","unstructured":"Gelissen LMY, Toorop AA, Schipper PM, Hoitsma E, Zeinstra EMPE, van Rooij LC, et al. Low natalizumab trough concentrations are associated with reduced seroconversion of the John Cunningham virus in natalizumab-treated patients with multiple sclerosis. Journal of Neurology, Neurosurgery, and Psychiatry. 2025; 96: 1038\u20131045.","DOI":"10.1136\/jnnp-2024-335761"},{"key":"ref67","unstructured":"Carlson AK. Long-term safety risks among patients with multiple sclerosis treated with ocrelizumab: An observational study. In 41st Congress of the European Committee for Treatment and Research in Multiple Sclerosis and the 30th Conference of Rehabilitation in Multiple Sclerosis. Barcelona, Spain. 2025."},{"key":"ref68","unstructured":"Pirronello M. Breaking Inflammatory Cycles: Cladribine Targets Pathogenic B Cell Subsets in Multiple Sclerosis. In 41st Congress of the European Committee for Treatment and Research in Multiple Sclerosis and the 30th Conference of Rehabilitation in Multiple Sclerosis. Barcelona, Spain. 2025."},{"key":"ref69","unstructured":"Samara A. Relationship Between CSF Cellular Populations and MRI Biomarkers of MS Disease Severity: Insights from the CLOCK-MS Study. In 41st Congress of the European Committee for Treatment and Research in Multiple Sclerosis and the 30th Conference of Rehabilitation in Multiple Sclerosis. Barcelona, Spain. 2025."},{"key":"ref70","unstructured":"Barkhof F. The effect of cladribine tablets on brain volume over 4 years in the MAGNIFY-MS extension study. In 41st Congress of the European Committee for Treatment and Research in Multiple Sclerosis and the 30th Conference of Rehabilitation in Multiple Sclerosis. Barcelona, Spain. 2025."},{"key":"ref71","unstructured":"Montalban X. Cladribine tablets show low 4-year PIRA rates in MS: insights from pooled analyses of CLARIFY-MS and MAGNIFY-MS studies. In 41st Congress of the European Committee for Treatment and Research in Multiple Sclerosis and the 30th Conference of Rehabilitation in Multiple Sclerosis. Barcelona, Spain. 2025."},{"key":"ref72","unstructured":"Moreno I. Neurofilament light chain profile in cladribine-treated multiple sclerosis. In 41st Congress of the European Committee for Treatment and Research in Multiple Sclerosis and the 30th Conference of Rehabilitation in Multiple Sclerosis. Barcelona, Spain. 2025."},{"key":"ref73","unstructured":"Bollo L. Impact of the 2024 McDonald criteria revisions on multiple sclerosis diagnosis: a comparison with the 2017 criteria. In 41st Congress of the European Committee for Treatment and Research in Multiple Sclerosis and the 30th Conference of Rehabilitation in Multiple Sclerosis. Barcelona, Spain. 2025."},{"key":"ref74","unstructured":"Brownlee WJ. Real-world validation of the 2024 McDonald criteria in patients under evaluation for suspected multiple sclerosis. In 41st Congress of the European Committee for Treatment and Research in Multiple Sclerosis and the 30th Conference of Rehabilitation in Multiple Sclerosis. Barcelona, Spain. 2025."},{"key":"ref75","unstructured":"Solomon AJ. Global Access to Paraclinical Diagnostic Testing for Multiple Sclerosis: Results of the 2024 Multiple Sclerosis International Federation Atlas of MS Topical Survey. In 41st Congress of the European Committee for Treatment and Research in Multiple Sclerosis and the 30th Conference of Rehabilitation in Multiple Sclerosis. Barcelona, Spain. 2025."},{"key":"ref76","unstructured":"Vilaseca A. TRUE-MOGAD Score: A Novel Scoring System to Discriminate True from False Positive MOG Antibody Testing. In 41st Congress of the European Committee for Treatment and Research in Multiple Sclerosis and the 30th Conference of Rehabilitation in Multiple Sclerosis. Barcelona, Spain. 2025."},{"key":"ref77","unstructured":"Portaccio E. A study with data from the Italian MS Register wins the ECTRIMS\u2019 Best Poster Award. In 41st Congress of the European Committee for Treatment and Research in Multiple Sclerosis and the 30th Conference of Rehabilitation in Multiple Sclerosis. Barcelona, Spain. 2025."},{"key":"ref78","unstructured":"Kreiter D. Risk of disability progression and therapy escalation in MS patients with spinal cord lesions at first presentation. An MSBase registry study. In 41st Congress of the European Committee for Treatment and Research in Multiple Sclerosis and the 30th Conference of Rehabilitation in Multiple Sclerosis. Barcelona, Spain. 2025."},{"key":"ref79","unstructured":"Engels D. Rituximab Dosing in Aquaporin-4-IgG\u2013Seropositive Neuromyelitis Optica Spectrum Disorder: Longer Infusion Intervals Reduce Infection Probability Without Compromising Treatment Effectiveness. In 41st Congress of the European Committee for Treatment and Research in Multiple Sclerosis and the 30th Conference of Rehabilitation in Multiple Sclerosis. Barcelona, Spain. 2025."},{"key":"ref80","unstructured":"Trogu F. Serum neurofilament light and glial fibrillary acidic protein levels remain stable with extension of B cell-depletion dosing intervals to 1-2 years in people with MS. In 41st Congress of the European Committee for Treatment and Research in Multiple Sclerosis and the 30th Conference of Rehabilitation in Multiple Sclerosis. Barcelona, Spain. 2025."}],"container-title":["Revista de Neurolog\u00eda"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.imrpress.com\/journal\/RN\/81\/8\/10.31083\/RN55658","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T11:04:47Z","timestamp":1788433487000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.imrpress.com\/journal\/RN\/81\/8\/10.31083\/RN55658"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,20]]},"references-count":80,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2026]]}},"alternative-id":["S0210-0010(26)00134-9"],"URL":"https:\/\/doi.org\/10.31083\/rn55658","relation":{},"ISSN":["0210-0010","1576-6578"],"issn-type":[{"value":"0210-0010","type":"print"},{"value":"1576-6578","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,20]]},"article-number":"55658"}}